Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis
Abstract Hereditary transthyretin (TTR) amyloidosis (ATTRv) is an autosomal dominant, systemic disease transmitted by amyloidogenic mutations in the TTR gene. To prevent the otherwise fatal disease course, TTR stabilizers and mRNA silencing antisense drugs are currently approved treatment options. W...
Enregistré dans:
Auteurs principaux: | , , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMC
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/9fb44f289ffd423bb7e7aa14a4bebefc |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Soyez le premier à ajouter un commentaire!